Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications

Elsa Bernard, Robert P. Hasserjian, Peter L. Greenberg, Juan Esteban Arango Ossa, Maria Creignou, Heinz Tuechler, Jesús Gutiérrez-Abril, Dylan Domenico, Juan Santiago Medina-Martinez, Max Fine Levine, Konstantinos Liosis, Noushin Farnoud, Maria Sirenko, Martin Jädersten, Ulrich Germing, Guillermo F. Sanz, Arjan A Van de Loosdrecht, Yasuhito Nannya, Olivier Kosmider, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold Kunal Elias, Detlef Thomas Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia Klimek, Fabio P S Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Sole, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee Yung Shih, Michaela Fontenay, Joop H Jansen, José Cervera, Norbert Gattermann, Benjamin L Ebert, Rafael Bejar, Luca Malcovati, Seishi Ogawa, Mario Cazzola, Eva S Hellstrom-Lindberg, Elli Papaemmanuil

Blood blood.2023023727.

https://doi.org/10.1182/blood.2023023727

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan Esteban Arango Ossa, Olivier Kosmider, Robert P Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo F. Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Andrea Pellagatti, Harold Kunal Elias, Detlef Thomas Haase, Birgitta Sander, Elisa Orna, Katharina Zoldan, Lea Naomi Eder, Wolfgang R Sperr, Renate Thalhammer, Christina Ganster, Lionel Adès, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety H Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia Klimek, Fabio P S Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Sole, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H Jansen, José Cervera, Benjamin L Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva S Hellstrom-Lindberg, Elli Papaemmanuil, Ronald Feitosa Pinheiro

Blood blood.2023023723.

https://doi.org/10.1182/blood.2023023723

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Yazan F. Madanat, Tymara Berry, Faye M. Feller, Libo Sun, Qi Xia, Ying Wan, Fei Huang, Michael R. Savona, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 4603.

https://doi.org/10.1182/blood-2023-179378

Published: 2023

Journal Articles

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Sterling Rosqvist, Victoria A. Vardell, Eric Anto, Gliceida Galarza Fortuna, Douglas Peters, Charlotte B Wagner, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Michael R. Savona, Kelley Julian, Brian McClune, Ghulam Rehman Mohyuddin, Amandeep Godara, Muhamed Baljevic, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4718.

https://doi.org/10.1182/blood-2023-190746

Published: 2023

Journal Articles

UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes

Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango Ossa, Olivier Kosmider, Robert Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Yung Follo, Felicitas Thol, Lurdes Zamora, Andrea Pellagatti, Harold K Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Sole, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B Beck, Eva Hellstrom Lindberg, Elli Papaemmanuil

Blood (2023) 142 (Supplement 1): 1862.

https://doi.org/10.1182/blood-2023-182949

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Blood (2023) 142 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2023-186340

Published: 2023

Journal Articles

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Blood (2023) 142 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2023-181673

Published: 2023

Journal Articles

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Blood (2023) 142 (Supplement 1): 5594.

https://doi.org/10.1182/blood-2023-189808

Published: 2023

Journal Articles

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Uwe Platzbecker, Rami S. Komrokji, Amer M. Zeidan, Pierre Fenaux, Mikkael A. Sekeres, Michael R. Savona, Yazan F. Madanat, Anna Jonášová, Thomas Illmer, Laurie Sherman, Tymara Berry, Jennifer Riggs, Qi Xia, Shyamala Navada, Ying Wan, Fei Huang, Faye M. Feller, Valeria Santini

Blood (2023) 142 (Supplement 1): 4605.

https://doi.org/10.1182/blood-2023-181154

Published: 2023

Journal Articles

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Rami S. Komrokji, Valeria Santini, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, Tymara Berry, Laurie Sherman, Shyamala Navada, Faye M. Feller, Libo Sun, Qi Xia, Ying Wan, Fei Huang, Amer M. Zeidan, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 194.

https://doi.org/10.1182/blood-2023-181237

Published: 2023

Journal Articles

Engaging Underrepresented Patients in Hematology Clinical Trials through the LLS Impact (Influential Medicine Providing Access to Clinical Trials) Research Grant: A Multi-Institutional Effort

Blood (2023) 142 (Supplement 1): 7237.

https://doi.org/10.1182/blood-2023-191067

Published: 2023

Journal Articles

Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Blood (2023) 142 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2023-186875

Published: 2023

Journal Articles

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Gail J. Roboz, Janelle Meyer, Winny Chan, Beloo Mirakhur, Yuri Sano, Aram Oganesian, Harold N. Keer, Michael R. Savona

Blood (2023) 142 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2023-178024

Published: 2023

Journal Articles

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Blood (2023) 142 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2023-178728

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Amer M. Zeidan, Michael R. Savona, Yazan F. Madanat, Pierre Fenaux, Rami S. Komrokji, Anna Jonášová, Thomas Illmer, Libo Sun, Tymara Berry, Faye M. Feller, Shyamala Navada, Valeria Santini, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 6478.

https://doi.org/10.1182/blood-2023-180962

Published: 2023

Journal Articles

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

David L. Grinblatt, Gail J. Roboz, Daniel A. Pollyea, Mikkael A. Sekeres, Bart L. Scott, Karen Seiter, Amer M. Zeidan, Jay L. Patel, Guillermo Garcia-Manero, Rami S. Komrokji, Michael R. Savona, Irene S. Degutis, Pavel Kiselev, Edward Yu, Willem Heydendael, Ying Qiu, Sara Vergara, Ali McBride, Harry P. Erba

Blood (2023) 142 (Supplement 1): 593.

https://doi.org/10.1182/blood-2023-189963

Published: 2023

Journal Articles

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari, Amir T. Fathi, Kapil N. Bhalla, Samuel Agresta, Sarah Reilly, Caroline Almon, Murphy Hentemann, Denice Hickman, Dillon Corrigan, Meghan Macaraeg, Jessica Piel, Kim Horrigan, Salah Nabhan, Paul Martin, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2023-178090

Published: 2023

Journal Articles

DNMT3A R882H Exhibits Greater Inflammatory Potential Than R882C in Primary Hematopoietic Stem and Progenitor Cell Knock-in Model and Population Data

Blood (2023) 142 (Supplement 1): 815.

https://doi.org/10.1182/blood-2023-187244

Published: 2023

Journal Articles

Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database

Blood (2023) 142 (Supplement 1): 324.

https://doi.org/10.1182/blood-2023-180299

Published: 2023

NARROW

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Engaging Underrepresented Patients in Hematology Clinical Trials through the LLS Impact (Influential Medicine Providing Access to Clinical Trials) Research Grant: A Multi-Institutional Effort

Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

DNMT3A R882H Exhibits Greater Inflammatory Potential Than R882C in Primary Hematopoietic Stem and Progenitor Cell Knock-in Model and Population Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only